You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Piper Sandler
since
auto-detected in 32 stories
25 days ago
A push to rake in more revenue and lower its operating costs should give the company's shares a big bump, per Piper Sandler.
53 days ago
'Grand Theft Auto VI' maker's stock is a buy ahead of highly anticipated game release, says Piper Sandler ○
The investment firm initiated coverage of the video game maker with an overweight rating.
3 months ago
This cloud stock is cheap and will be an AI winner, says Piper Sandler ⊕
The investment firm upgraded cloud name to overweight from neutral.
This biotech firm has room to run, even as its drug royalties are set to shrink ⊕
Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support its growth, per Piper Sandler.
Nike shares are still not cheap after 30% drawdown this year, says Piper Sandler ○
Nike could struggle with sales as the athleisure market becomes more crowded and demand for sports-focused loungewear moves past its peak, per Piper Sandler.
Avoid these stocks in the second quarter, says Piper Sandler ○
These stocks are underperformers in their respective sectors
4 months ago
Bill Ackman wants a little Berkshire of his own. Piper Sandler says there's a 'secret sauce' ⊖
found
Piper Sandler believes Ackman's ambition will depend largely on his ability to keep insurance risk low while letting investment returns do the heavy lifting.
5 months ago
Buy the dip: Microsoft is the best 'pure play' on AI adoption, says Piper Sandler ⊕⊕
The investment firm named shares a top pick following the stock’s big post-earnings fall last week.
7 months ago
Here's an unusual AI play for 2026: Glasses ⊕
Eyewear stock Warby Parker has room to run and offers exposure to the AI trade, according to Piper Sandler. The firm will roll out its AI glasses next year.
This health tech stock is a buy and can surge nearly 50% from here, says Piper Sandler ⊕
Piper Sandler's revised price target sees shares of Oscar Health soaring 49%.